AstraZeneca plans to list its shares in New York while keeping its London listing, a move that could allow easier access to ...

GSK announced that Luke Miels, the company’s chief commercial officer, will take over as CEO on Jan. 1, replacing Emma ...

Francer is Lilly’s vice president, head of global regulatory policy and strategy. Cruz is Lilly’s senior vice president, ...

A federal judge in Texas threw out a Biden-era rule last week that would have ramped up federal audits of private Medicare ...

It’s the question biotech investors were wagging about all Monday after Tidmarsh used his personal LinkedIn page to raise ...

Study finds 99% of all heart attacks, heart failure, or strokes occur in people with "suboptimal" blood pressure, cholesterol ...

The Danish company Genmab plans to buy Merus, the maker of a promising head and neck cancer drug, in a deal worth roughly $8 ...

Insurance companies continue to innovate. On Oct. 1, Cigna will roll out a policy that tracks how physicians bill. It will ...

Lisa Suennen: "If this is going to make it a lot more expensive to get the same outcome, that is not a good investment." ...

In today's Morning Rounds newsletter, burning questions on MMR vaccines, a perimenopause business boom, and more.

The more we talk, debate, even sometimes argue, the more we can live well with a mind altered by these progressive, disabling ...

Perimenopause brings real symptoms and a booming market of supplements, apps, and therapies. What’s hype, what’s helpful, and ...